About SEC14-like protein 2
SEC14-like protein 2 (SEC14L2) is a protein
from Homo sapiens identified by UniProt accession
O76054, 403 residues long.
MolForge cross-references it against 0 known binders and
73 disease associations.
Target properties
| Protein name | SEC14-like protein 2 |
| UniProt accession | O76054 |
| Gene | SEC14L2 |
| Organism | Homo sapiens |
| Length | 403 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (73)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.40
- sex hormone-binding globulin measurement · score 0.24
- neuroinflammatory disorder · score 0.15
- hemoglobin measurement · score 0.08
- open-angle glaucoma · score 0.07
- white matter microstructure measurement · score 0.07
- BMI-adjusted waist circumference · score 0.06
- platelet component distribution width · score 0.06
- calcium measurement · score 0.06
- hypertriglyceridemia 2 · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O76054-F1 | alphafold | PREDICTED | 95.59 | — |
Amino-acid sequence (403 residues)
MSGRVGDLSP RQKEALAKFR ENVQDVLPAL PNPDDYFLLR WLRARSFDLQ KSEAMLRKHV EFRKQKDIDN IISWQPPEVI QQYLSGGMCG YDLDGCPVWY DIIGPLDAKG LLFSASKQDL LRTKMRECEL LLQECAHQTT KLGRKVETIT IIYDCEGLGL KHLWKPAVEA YGEFLCMFEE NYPETLKRLF VVKAPKLFPV AYNLIKPFLS EDTRKKIMVL GANWKEVLLK HISPDQVPVE YGGTMTDPDG NPKCKSKINY GGDIPRKYYV RDQVKQQYEH SVQISRGSSH QVEYEILFPG CVLRWQFMSD GADVGFGIFL KTKMGERQRA GEMTEVLPNQ RYNSHLVPED GTLTCSDPGI YVLRFDNTYS FIHAKKVNFT VEVLLPDKAS EEKMKQLGAG TPK
Explore SEC14-like protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets